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1. INTRODUCTION 
1.1. HUMAN GUT MICROBIOTA PATHOPHYSIOLOGY 
A large microbial ecosystem, housing several trillion microbial cells, is 
harboured in human intestinal tract, collectively constituting gut 
microbiota. Data from more than one thousand persons from United 
States, China and Europe, identified nearly 10 million microbial genes in 
the fecal microbioma, including harmless symbionts, commensals and 
opportunistic pathogens1.  
Number of bacteria varies among the length of the gastrointestinal tract, 
reaching the highest load in the colon (Figure 1).  
Interestingly, it has been shown that gut microbiota has several essential 
functions in humans such as in the host immune response2, protection 
against pathogens overgrowth3, regulation of intestinal endocrine 
functions4, metabolic and excretion functions5.  
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Figure 1. The human gastrointestinal tract and its microbiota 
Concerning gut microbiota composition, a significant interindividual 
variation has been reported, with each person having a unique gut 
microbioma6. However, despite differences among individuals, functional 
capacities are similar in healthy persons7. Moreover, significant changes 
occur in the same individual from infancy to elderly, with age-
differentiated microbiologically communities, with different bacteria strains 
and proportions8,9. In the elderly, the gut microbiota become 
compositionally unstable and less diverse, events that are associated with 
coexisting conditions and age-related declines in immunocompetence 
(Figure 2)10.  
Different exogenous and endogenous factors may significantly modify 
microbiota composition, thus leading to dysbiosis. These factors include 
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mode of delivery of a neonate11, host genetic features12, host immune 
response13, drugs14, diet15, etc.  
Dietary habits, indeed, strongly influence the selection of gut microbiota, 
with studies showing that meat consumption favors bilemetabolizing 
expansion (which may be associated to the development of inflammatory 
bowel disease), while vegetable consumption favors plant polysaccharide-
fermenting organisms. It has also been reported that persons have very 
different metabolic responses to identical meals14.  
 
Figure 2. Changes in microbiota composition according to ages. 
  
Considering those several physiological functions of gut microbiota in 
human health, it is not surprising that dysbiosis has been also associated 
in multiple studies to a wide spectrum of common chronic disorders, 
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including atherosclerosis16, metabolic disorders17, asthma18 and autism 
spectrum disorders19.  
The “common ground” hypothesis provides a possible pathogenetic 
explication on the relation between dysbiosis and chronic diseases. 
Increase in gut permeability, for example due to mucosal inflammation, 
diet or chronic infections, may favor modification and development of an 
aberrant gut microbiota20. In persons genetically predisposed to one or 
more chronic disorders, these modifications may favor the expansion of 
opportunistic and dysbiotic pathobionts, contributing to elicit specific 
disorders in predisposed individuals.  
Interestingly, transplantation of the dysbiotic disease-associated gut 
microbiota to a genetically susceptible rodent host, allowed reproduction 
of disease phenotype, thus supporting this hypothesis and showing that 
transfer of gut microbiota from one to another is possible. Therefore, 
much effort is currently concentrated on exploring potential causality and 
related microbiota-mediated disease mechanisms, with the hope that an 
improved understanding will fuel the conception and realization of novel 
therapeutic and preventive strategies. 
1.2. DYSBIOSIS IN HEMATOLOGICAL DISEASES 
Important dysbiosis is observed in patients diagnosed with hematological 
malignancies needing treatments with intensive chemotherapies or in 
patients undergoing allogeneic hematopoietic stem cell transplantation 
(allo-HSCT).  
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One of the most frequent side effects of chemotherapy is, indeed, 
mucositis, also referred as mucosal barrier injury. It is characterized by 
both inflammation and cell loss in the epithelial barrier lining the 
gastrointestinal tract. Clinically, mucositis is associated with bacteremia, 
malnutrition, use of total parenteral nutrition, and an increment in the use 
of intravenous analgesics.  
Historically, research has focused on oral mucositis. More recently, 
attention has been drawn towards the pathophysiology and clinical 
symptoms of intestinal mucositis, which is characterized by symptoms like 
nausea, bloating, vomiting, abdominal pain and severe diarrhea.  
Recent studies have shown that chemotherapeutic agents have an effect 
on gut microbiota composition inducing significant changes in commensal 
intestinal bacteria, favoring mucositis and its severity21. It has also been 
shown that some intestinal bacteria play a role in the metabolism of 
certain chemotherapeutic agents. The outgrowth of these bacteria might 
lead to the formation of active toxic metabolites of the chemotherapeutic 
drug, which directly affects the progression of intestinal mucositis22. 
However, the commensal intestinal microbiota might also have beneficial 
effects on the development of intestinal mucositis, as the mere presence 
of resident intestinal bacteria might offer protection against its 
development.  
The epithelial barrier lining the gastrointestinal tract is composed of a 
single layer of epithelial cells intertwined by tight junctions, thus 
functioning as a mechanical barrier whose action is further increased by a 
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mucus layer. When inflammation of gut mucosa occurs (i.e. after 
chemotherapy), Toll-like receptors that are present at the outer 
membrane of the epithelial cells may interact with intestinal bacteria. This 
interaction favors the activation of nuclear factor kappa B (NFkB) which 
results in the development of an inflammatory response. However, 
multiple intestinal bacteria are capable of decreasing NFkB activation, 
resulting in a diminished production of inflammatory cytokines.  
Intestinal permeability increases after chemotherapy treatment, probably 
subsequent to intestinal villous atrophy after epithelial loss. However, the 
resident intestinal microbiota has also been proposed to directly influence 
intestinal permeability, with some bacteria and their products increasing 
permeability and others attenuating cellular atrophy and strengthening 
tight junctions, thus highlighting different roles of gut microbiota in 
mucositis pathophysiology and severity.  
Therefore, chemotherapy-induced dysbiosis may finally also be explained 
by the fact that it induces a deregulation in intestinal microbial 
homeostasis, with disappearance of bacteria implicated in the protection 
of enterocytes against harmful stimuli. The exact nature and relevance of 
the relationship between chemotherapy-induced mucositis, inflammation 
and intestinal microbiota is subject to ongoing research.  
In patients undergoing allogeneic hematopoietic stem cell transplantation 
(allo-HSCT) for hematologic malignancies, use of conditioning regimens 
and wide-spectrum antibiotics, may similarly impact on gut microbiota 
composition, inducing significant dysbiosis. During the aplastic phase 
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following allo-HSCT, for example, the diversity of gut ecosystem 
decreases of nearly 30%, with invasion by new species and loss of 
commensal bacteria (Figure 3).  
Furthermore, in this particular population, development of gut graft-
versus-host disease (GVHD) may also result in significant damage to gut 
epithelial cells and modifications in pathogen flora, with consequent 
promotion of proliferation of alloctonous opportunistic bacteria.  
However, this condition does not seem irreversible, with reconstruction of 
a “healthy” microbiota (in the absence of significant complications favoring 
and perpetuating dysbiosis) during the 60-100 days following allo-HSCT. 
Studies showed that gut microbiota composition is predictive of the overall 
mortality in transplanted patients. Indeed, in a cohort of 80 transplanted 
adults, low-, intermediate- and high-intestinal diversity of the gut 
microbiota at the engraftment defined three groups with different overall 
survival at 3 years, 36, 60, and 67%, respectively. The increase of the 
mortality rate in this study was primarily due to transplant-related causes, 
suggesting a link between that lack of microbial diversity and infection 
and/or GvHD23.  
According to GVHD, indeed, it has been largely demonstrated that certain 
bacteria species are more frequently found in patients developing GVHD, 
with ecosystems that significantly differ from those of patients not 
developing GVHD. Similarities with gut microbiota of patients diagnosed 
with intestinal bowel disease with those of patients developing GVHD have 
also been reported, including reduced microbial richness, relative 
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abundance of Gram-positive bacteria that were associated in both 
situations to increased intestinal inflammation24.  
Although associations between microbiome diversity and outcomes of allo-
HSCT do not demonstrate causality, they provide data to support clinical 
evaluation as to whether these relationships can be modified to influence 
outcomes for patients.  
 
Figure 3. Gut microbiota modifications after allogeneic       
hematopoietic stem cell transplantation. 
1.3. DEVELOPING STRATEGIES TO ADDRESS MICROBIOTA: FECAL 
MICROBIOTA TRANSPLANTATION AND THE EXAMPLE OF 
CLOSTRIDIUM DIFFICILE INFECTION  
Active research on efficacious strategies to modulate and correct dysbiosis 
is currently ongoing. A promising strategy is represented by fecal 
microbiota transplantation (FMT) which consists in transfer of stools and 
bacteria from a healthy individual to another experiencing dysbiosis, with 
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the rationale to allow gut microbiota modulation with subsequent 
reconstitution of a healthy microbiota25. 
The use of FMT for human disease goes back many centuries. Two chinese 
doctors firstly described the use of human fecal suspension in different 
preparations to successfully treat patients who had food poisoning or 
severe diarrhea. During World War II, German soldiers in Africa were 
recommended by Bedouins to treat bacterial dysentery with “consumption 
of fresh, warm camel feces”26. In 1958, an American surgeon used fecal 
enemas to treat four patients who had developed fulminant 
pseudomembranous enterocolitis after antibiotic use; the treatment 
resulted in a rapid resolution of symptoms27.  
In 2013, the first randomized controlled trial using FMT in Clostridium 
difficile infection (CDI) was published28. Since then, FMT has been 
investigated as a possible therapy in a variety of diseases with the largest 
experience reported in cases of severe recurrent diarrhea caused by 
antibiotic-resistant CDI, favored by the use of antibiotics25.  
Clostridium difficile is a ubiquitous, anaerobic, Grampositive, cytotoxin-
producing bacillus which exists in both a vegetative form (the toxin-
producing replicative state) and a spore form. The latter is particularly 
resistant to destruction even with antiseptics. This allows the organism to 
persist in the gut and the environment. If the gut microbiota remains 
disturbed after CDI therapy, the spores can germinate to the vegetative 
form, resulting in recurrent disease.  
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With the rationale of restoring gut microbiota in order to protect the 
intestinal lining and help eliminate or prevent residual spores from causing 
recurrent disease, use of FMT allowed infection eradication in >90% of 
patients, also decreasing the economic burden of this infection on 
healthcare systems28,29.  
In two randomized controlled trials, FMT was associated to a success rate 
of > 90% as compared to nearly 30% with the use of oral vancomycine in 
patients with recurrent CDI28,30. Despite these studies have small samples 
as they were early stopped, further studies, also grouped in metanalysis 
and systematic reviews, confirmed resolution rates of recurrent CDI with 
FMT of nearly 90%31.  
Since the introduction and success of FMT in CDI, its use has been 
subsequently investigated in other chronic diseases, such as inflammatory 
bowel disease (IBD) or decolonization from multidrug-resistant bacteria 
(MDRB) 32,33.  
However, the dissemination of FMT in clinical practice is actually restricted 
by regulatory and bureaucratic issues (mainly related to costs, donor 
programme, safety control). To date FMT has not yet undergone the 
traditional regulatory approval process of pharmaceutical products with 
sequential testing leading to large phase 3 trials assessing efficacy and 
safety prior to clinical utilization34,35.  
Authoritative published guidelines and recommendations have been 
released as expert opinions rather than evidence-based consensus 
reports. Despite the existence of European consensus report on clinical 
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indications, methodological aspects and donor selection, there is still no 
real consensus, with large differences existing among centers worldwide36.  
For all these reasons, in all cases of planned FMT, local ethical approval 
and patient and donor informed consent should be obtained and FMT 
should be done in specialized centers. A multidisciplinary team, including 
gastroenterologist, microbiologist and infectious diseases physicians, 
should be encouraged in centers performing FMT.  
The only clinical indication with sufficient evidence of benefit from the 
implementation of FMT in clinical practice to date is CDI, while its use in 
all other situations remains still investigational. 
1.3.1. Safety of FMT  
Despite initial concerns about the safety of FMT, most studies finally 
highlighted this procedure as being globally safe. To date, no cases of 
transmitted infectious diseases due to FMT have been reported. Minor 
short-term adverse events such as diarrhea, flatulence, abdominal 
discomfort, and cramping are common after FMT. Most of these adverse 
events are self-limiting and disappear within 2 days after FMT.  
However, cases of fever as well as Gram-negative bacteraemia and 
perforation have been described. A case of death after regurgitation of 
faecal material infused into the duodenum under general anaesthesia has 
also been reported. After delivering donor stool via a pre-existing 
nasogastric tube, another patient developed septic shock and toxic 
megacolon and died after colonic resection. Finally, a patient had a severe 
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septic shock due to the faecal aspiration following endoscopic peroral 
jejunal FMT37,38,39. 
A systematic review analysing the clinical efficacy and safety of FMT 
identified 45 studies40. Adverse events were rare, being reported in 34 out 
of 45 studies. In total, 35 out of 1029 patients, were reported to have 
died and 10 patients were hospitalised during follow-up. One patient died 
from aspiration during sedation for FMT administered via colonoscopy, 
which was considered to be related to the FMT procedure. Four patients 
were reported to have died from complicated CDI with small bowel 
involvement confirmed at autopsy, a toxic megacolon due to persistent 
CDI one month after FMT, and complicated CDI not further specified. A 
severely ill patient treated with FMT for CDI, died of a peritonitis which 
could be related to treatment. Reported adverse events associated with 
FMT were mostly self-limiting and occurred frequently within hours after 
infusion. Intestinal reported symptoms were: bloating, flatulence, belching 
and abdominal cramps, abdominal discomfort, irregularity of bowel 
movements and vomiting. In 11 patients fever, without other clinical 
symptoms or signs of sepsis, was reported during and up to one day after 
FMT. No causative agents were identified by blood culture, but a rise in C-
reactive protein was measured in some of these patients. Fever 
disappeared within 3 days in all patients. Overall, based on the systematic 
review, the safety profile of FMT proved to be excellent.  
However, it is worth underlying that route of fecal infusion may influence 
appearance of adverse events after FMT. In another systematic review, 
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indeed, patients receiving infusion via upper gastrointestinal routes were 
more likely to develop adverse events as compared to those via lower 
gastrointestinal routes (44% versus 21%)41.  
Interestingly, more recent use of frozen capsules FMT for the treatment of 
CDI showed efficacy with a favorable safety profile consisting of few mild 
abdominal cramping and bloating, and may therefore represent in the 
future a safer and more easily available strategy for FMT, but more 
studies are needed42.  
Regarding very-long-term risks (more than 5 years), little evidence is 
available43. Despite anecdotal reports of “FMT-related diseases”, with 
transmission of malignant, autoimmune, metabolic or neuropsychiatric 
diseases shown in animal models, causality to FMT remains unclear.  
1.3.2. Use of FMT in hematologic patients 
Many concerns were initially raised about the feasibility of FMT in 
immunocompromised patients, such as those affected by hematological 
malignancies, because of the theoretic potential for local and bloodstream 
infections but recent case reports revealed the efficacy and safety in this 
particular population44,45,39. However, to date use of FMT in this setting 
still remains investigational. 
One case-series study reported on FMT use in 80 immunocompromised 
patients39. Although serious adverse events (2 deaths and 10 
hospitalizations) occurred in 12 patients (15%), none seemed to be 
directly related to FMT. Non-serious adverse events were reported for 12 
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patients (15%); four were considered related to FMT, five were possibly 
related and three were unrelated to FMT.  
A retrospective study done on immunocompromised and non-
immunocompromised patients who received FMT for recurrent CDI 
concludes that response to FMT is equivalent in the two populations, with 
similar safety46.   
Heterologous FMT has been evaluated in 14 immunocompromised patients 
after allo-HSCT47,48 without any severe adverse effect reported. 
Webb et al. reported the use of heterologous FMT in 7 patients with 
recurrent CDI after allo-HSCT. FMT was administered via the naso-jejunal 
route in 6 of 7 patients. No serious adverse events were noted in these 
immunocompromised patients. Diarrhea was improved in all patients, with 
no recurrence in most of the patients. Therefore, FMT appears to be safe 
for recurrent CDI also in immunocompromised allo-HSCT patients49. 
More recently, due to the aforementioned dysbiosis related to GVHD in 
transplanted patients, use of FMT has also been explored as a treatment 
of patients presenting steroid refractory GVHD. A pilot study, indeed, 
investigated whether empiric third-party frozen FMT capsules would be 
safe and feasible after allo-HSCT, and would be able to restore recipient 
microbiome diversity50, with promising results prompting to the activation 
of a prospective European study further exploring this issue 
(NCT03359980). 
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1.3.3. Use of fecal microbiota transplantation for the 
eradication of multidrug-resistant bacteria in 
hematological patients 
Pretransplant conditioning and intensive chemotherapies for acute 
leukemias, indeed, induce aplasia causing important predisposition to 
disseminated infections, also favored by the aforementioned modifications 
in epithelial cells and by mucositis. These modifications render easier that 
commensal bacteria may invade underlying tissues and the bloodstream. 
This prompts the immediate introduction of large spectrum antibiotics in 
order to treat the infection. Use of antibiotics, not only in the hematologic 
field, is a well-known cause of dysbiosis, contributing to the selection and 
persistent colonization from multidrug resistant bacteria (MDRB) 51.  
During the last decades, the prevalence of MDRB has largely increased, 
becoming a serious worldwide problem, significantly impacting on the 
healthcare system52.  
In order to prevent spreading of these bacteria to other patients, 
preventive measures are warranted, including patient isolation, limitations 
of transfer to other healthcare centers and management by dedicated 
staff, with consequent related increased healthcare costs, which are not 
easily affordable in most centers53. According to French 
recommendations54, for example, patients colonized with MDRB are not 
easily admitted in healthcare facilities not disposing of dedicated staff.  
Under physiological conditions, commensal microbiota prevents gut 
colonization from MDRB. Patients undergoing allo-HSCT are at even higher 
risk of dysbiosis due to their profound immune depression55. In case of 
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bloodstream infections from MDRB, outcomes are even poorer, with 
consequent increased mortality56. An Italian study, for example, showed 
that carbapenemase producing (CP-) bacteria, including Pseudomonas 
aeruginosa, were independent predictors of death in patients diagnosed 
with acute leukemia, while this was not observed in case of extended-
spectrum β-lactamase (ESBL-) enterobacteriaceae57.   
Spontaneous decolonization is a long process, with variable durations 
according to the healthcare system where the patient is hospitalized and 
also depending on associated disease and concomitant treatments. In 
patients treated in long-term care facilities and intensive care units, for 
example, it has been reported a median duration of colonization with 
MDRB of 144 days, with spontaneous clearance in only 9% of patients58. 
In the hematological setting, an even longer time of 387 days was 
required to obtain negative rectal swab cultures from individuals who were 
originally colonized with MDRB59. 
New classes of antibiotics are under study to treat infections related to 
MDRB, and active research is ongoing to find effective decolonization 
strategies60. The use of oral gentamicin or colistin had been initially 
proposed in some MDR-gram negative strains, but failure is common, and 
the risk of selecting gentamicin- or colistin-resistant strains may also be 
present61,62,63.  Due to the emergence of new resistant strains, use of oral 
decontaminating agents is not adviced in clinical practice and other 
decolonizating strategies have been explored, with promising results with 
the use of FMT for eradication of MDRB56.  
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Recently, Bilinski et al. reported the results of a prospective study 
evaluating FMT in 20 patients with MDRB gut colonization and 
contemporarily affected by hematologic malignancies. Overall 25 FMT 
were performed and 15/20 patients experienced complete MDRB 
decolonization64, including some of them with GVHD after allo-HSCT.  
One can speculate that early initiation of FMT therapy could possibly spare 
infectious complications from MDRB and decrease the economic burden 
related to these bacteria. 
With this rationale, we retrospectively collected data on our experience 
with FMT in patients diagnosed with hematologic malignancies and 
colonized or experiencing systemic infections of MDRB.   
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2. MATERIALS AND METHODS   
In this single-center study, we retrospectively analyzed data on all 
consecutive adult patients diagnosed with hematologic malignancies who 
underwent FMT before or after allo-HSCT due to MDRB colonization.  
In our center microbiological screening is performed weekly in all 
inpatients, in order to identify asymptomatic carriers with high risk of 
spreading MDRB to other patients, with consequent preventive measures 
in positive patients in order to limit MDRB spread.   
Screening modalities consisted of weekly rectal swab. After MDRB 
identification, patients colonized with vancomycin-resistant (VRE) or 
carbapenemase-producing enterobacteriaceae (CPE) were cohorted and 
cared for by dedicated staff, as these two classes of bacteria are classified 
as emerging XDR (eXDR), i.e. bacteria that present an emerging infection 
control challenge widely in France. Of note, when those patients are 
candidates to rehabilitation centers before being discharged at home, they 
cannot be easily admitted to other healthcare facilities that often do not 
dispose of dedicated staff.  
Furthermore, in contact patients, defined as those patients having shared 
paramedical and/or medical healthcare workers with one or more patients 
colonized with VRE or CPE, cohorting is also warranted, with initial caring 
by another dedicated staff until three negative screening tests. 
According to French regulations, each patient case was extensively 
discussed and approved as part of an "RCP" (Réunion de Concertation 
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Pluridisciplinaire") which is a sort of large multidisciplinary meeting 
(hematologist, gastroenterologist, pharmacist) aimed to discuss difficult 
cases and approve unusual therapeutic procedures. The minutes and 
decisions of the RCP are recorded in writing, including the names of the 
participants and their feedback. Patients are informed about this 
discussion prior to signing the informed consent, which mentioned the 
theoretical risks of the procedure, due to the actual investigational use of 
FMT in the field of MDRB and in patients with hematologic malignancies. 
2.1. INCLUSION CRITERIA 
We considered eligibility to FMT in case of asymptomatic carriers or 
systemic infections from VRE, carbapenemase-producing 
Enterobacteriaceae (CPE) or CP-Pseudomonas aeruginosa. Rationales for 
FMT and MDRB decolonization were mainly to limit infectious 
complications related to these bacteria and to facilitate patients transfer in 
other departments such as intensive care units or rehabilitating centers.   
It is worth underlying that opportunistic saprophytic bacteria, such as CP-
Pseudomonas aeruginosa, have not been considered as eXDR according to 
French guidelines. However, it has been already reported that patients 
experiencing systemic infections from CP-Pseudomonas aeruginosa have a 
high risk of death, and in our Center three consecutive patients (data not 
published) died during the aplastic phase of allo-HSCT due to bloodstream 
fatal infections from CP-Pseudomonas aeruginosa.    
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For these reasons, patients colonized with CP- Pseudomonas aeruginosa 
were considered at high risk of fatal complications and, despite not 
needing isolation and caring by dedicated staff, FMT was also proposed to 
those patients experiencing systemic infections or in those colonized from 
CP-Pseudomonas Aeruginosa, in order to limit systemic infections. 
On the other hand, we did not consider colonization from ESBL-producing 
enterobacteriaceae as an indication for FMT as those patients do not need 
isolation according to French guidelines. However, for the purpose of the 
current report, we retrospectively registered in patients undergoing FMT 
for the aforementioned indications, if they were also colonized with ESBL-
producing bacteria in order to look if FMT also allowed decolonization from 
these bacteria.  
Timing for FMT was either before allo-HSCT in patients having undergone 
induction and consolidation chemotherapies, or after allo-HSCT.  
In patients initially achieving decolonization and then experiencing MDRB 
recurrence or in those patients for whom FMT was a failure, a second 
attempt could be proposed.   
A minimal platelet count of 20 x 109/L was preferred in order to proceed 
to the FMT and use of platelet transfusion to reach that threshold before 
FMT was allowed.  
2.2. DEFINITIONS 
For the purpose of this retrospective analysis, we also classified MDRB as 
multi-drug (MDR), extensive-drug (XDR) and pan-drug-resistant (PDR) 
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according to the definition proposed by Magiorakos et al. 65: MDR was 
defined as the presence of acquired non-susceptibility to at least one 
agent in three or more antimicrobial categories, XDR as non-susceptibility 
to at least one agent in all but two or fewer antimicrobial categories (i.e. 
bacterial isolates remain susceptible to only one or two categories) and 
PDR as non-susceptibility to all agents in all antimicrobial categories. 
Decolonization from VRE, CPE or CP-Pseudomonas aeruginosa after 
negative results on a minimum of three consecutive microbiological 
cultures (performed weekly) was defined as “major decolonization” while 
“persistent decolonization” was defined as the persistence of negative 
rectal swab until last follow-up after a first or second FMT, whenever this 
was feasible. In patients concomitantly colonized by ESBL-producing 
enterobacteriaceae, “concomitant decolonization” was defined as negative 
results on at least three consecutive rectal swabs after FMT.  
In patients achieving decolonization, rectal swabs and/or stool cultures 
were initially performed weekly and then at each follow-up visit. In 
patients considered as having achieved total and persistent 
decolonization, last follow-up for decolonization was considered as the 
date of the last available negative microbiological culture.  
Large spectrum antibiotics were discontinued in the recipients 48-72 hours 
prior to the procedure and, when possible, use of antibiotics was avoided 
during at least 72 hours after the procedure.  
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2.3. MICROBIOLOGICAL TESTING  
For each patient, one rectal swab specimen was plated onto selective 
media: a screening medium designed to detect ESBL-producing 
enterobacteriaceae, ChromID ESBL (bioMérieux) and another designed to 
detect CP-bacteria, ChromID CARBA SMART (bioMérieux). A second rectal 
swab was used in an enrichment procedure, consisting of an overnight 
culture at 37°C in a specific broth before plating onto a screening medium 
designed to detect VRE, ChromID VRE (bioMérieux). All plates were 
incubated overnight at 37°C. Colonies growing on these selective media 
were identified at the species level by MALDI-TOF spectrometry. The 
production of ESBL was determined by an antibiogram and visualization of 
the characteristic “champagne cork” synergy between amoxicillin-
clavulanate and third-generation cephalosporins disks. Carbapenemase 
production was determined by molecular analysis using the GeneXpert 
technology (Cepheid) and the Xpert Carba-R kit version 2 (detecting the 
most prevalent carbapenemases in France, OXA-48 and OXA-48-like 
enzymes, as well as NDM enzymes). Furthermore, VRE were also 
identified using the GeneXpert technology (Cepheid) and the Xpert 
VanA/VanB kit. 
2.4. DONOR SCREENING   
Stools were preferentially obtained from healthy related or unrelated 
donors. Of note, related donors not necessarily coincided with allo-HSCT 
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donors. According to regulatory recommendations, potential donors were 
selected after a previous questionnaire. Donor age was preferentially 
between 18 and 65 years. Excluded were people who had presented 
digestive disorders (i.e. diarrhea) within the 3 months prior to donation or 
having a chronic disease and/or chronic treatments, cases with antibiotic 
intake within 3 months before the donation, people having been living in 
the tropics during the three months prior to donation or having been 
hospitalized abroad for more than 24 hours in the 12 months prior to 
donation. History of typhoid fever was also considered as exclusion 
criteria.  
In people fulfilling inclusion criteria, a complete biological and 
microbiological assessment was then performed including:  serology for 
Treponema pallidum, human immunodeficiency virus, Human T-
Lymphotropic Virus, Hepatitis A, B and C, cytomegalovirus, Epstein-Barr 
virus, amebiasis, Strongyloides strecoralis ; stool examination for 
standard culture, Clostridium difficile, multi-resistant bacteria, norovirus, 
Cryposporidium, parasites. If the biological and microbiological panel was 
negative, a minimum of 50 g of stools were collected. 
Chronic treatments not considered as a contraindication for stools 
donation, were stopped one week before FMT was performed due to the 
absence of certain knowledge on their impact on gut microbiota.   
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2.5. PRODUCT PREPARATION 
Transplants are prepared in the Saint Antoine Hospital pharmacy 
according to recommendations from the French Group of FMT66. In case of 
freezing, the stool preparation are usually performed in two steps. In the 
first, preparation and freezing, the stools are manipulated in an extractor 
hood dedicated to this activity, in the 6 hours following emission. A total 
of 50-100g stools are weighted and mixed with a sterile cryopreservative 
saline solution (300mL glycerol+ saline solution 0.9% 10/90 V/V) using 
sterile blender, containers and medical devices (syringes, filters). The 
suspension is filtrated through sterile gauze compresses mounted in a 
funnel to remove solid residues, before freezing at -80°C.  If in screening 
tests an exclusion criterion is fulfilled, the suspension is destroyed. The 
second step of the preparation procedure starts the day before FMT, when 
the frozen microbiota solution is placed in a refrigerator (between 4 and 
8°C) for an overnight thawing.  The thawed suspension is then transferred 
either to an enema bag (lower gastro intestinal tract delivery) to which 
200mL of sterile saline solution are added, or to 50-mL syringes 
(colonoscopy or nasoduodenal delivery) as ready to be used. On the other 
hand, when FMT is performed with fresh stools, fecal materials need to be 
prepared the day of FMT within the 6 hours following stools emission. In 
this case stool preparation is performed in a single step, without freezing.   
28 
 
2.6. ADMINISTRATION OF THE FINAL PRODUCT 
Fecal material, prepared as described below, was delivered either by 
enema or via nasogastric tube. A bowel preparation was performed the 
day before the FMT by administration of 4 liters of polyethylene glycol 
(PEG) based solution (2 liters the night before and 2 liters the day of the 
procedure).  
In the case of enema administration, patients were positioned in lateral 
decubitus. A probe connected to the enema bag was then introduced up to 
the first 10-15 cm of the rectal ampulla. Duration of the administration 
varied from 15 to 30 minutes according to the final volume of the enema 
bag. After the procedure, patients were asked to hold the infused material 
for at least 2 hours. During this period, they were also asked to remain 
supine in order to minimize the urge to defecate and to periodically 
change position (i.e. each 30 minutes) in order to allow product diffusion 
in the colon.    
For nasogastric administration, patients had to fast for at least 12 hours 
before transplantation and they received proton pump inhibitors the day 
before and the morning of the FMT. Positioning of a nasogastric tube was 
done the day before FMT and radiological check of correct positioning was 
mandatory. Once patients conditions were considered favorable for the 
product administration (i.e. in the absence of gastrointestinal symptoms 
such as nausea or vomiting), this was made by 50 ml syringes. Once the 
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administration was completed, patients were kept in a 45° upright 
position for 4 hours after infusion in order to prevent material aspiration.  
2.7. SAFETY  
The safety of the procedure was also registered. For all patients, data on 
significant infections, defined as bacteriemias or sepsis occurring during 
the first 90 days after FMT were also collected. Febrile neutropenia or 
fever of unknown origin were not considered as significant infectious 
episodes but, when occurring during the first 90 days after FMT, they were 
also recorded. 
Adverse events were graded according to Common Terminology Criteria 
for Adverse Events (CTCAE). 
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3. RESULTS 
During the period between 2014 and 2017, 10 patients underwent FMT, 7 
due to gut colonization without systemic infection by either CPE 
(Escherichia coli, n=1; Citrobacter freundii, n=2; Klebsiella pneumoniae, 
n=1), or CP-Pseudomonas aeruginosa (n=1) or VRE (n=2) and 3 after 
having experienced systemic infections from CP-Pseudomonas aeruginosa. 
The median age at FMT was 48 (range 16-64) years. Four patients 
underwent FMT as a decolonization strategy before allo-HSCT, with a 
median interval from FMT to transplant of 28 (range 9-46) days. Of note, 
one patient was contemporarily colonized by three different CPE. Two 
patients started conditioning regimen 3 days after FMT and the other two 
after a month.  Six patients underwent FMT after allo-HSCT, with a 
median time from allo-HSCT to FMT of 163 (range 98-344) days. Of note, 
all patients undergoing FMT after allo-HSCT were still on 
immunosuppressive therapy at the time of FMT, with only one out of six 
presenting active grade IV steroid-dependent gut graft-versus-host 
disease (GVHD). Overall, six patients were also colonized by ESBL-
producing enterobacteriaceae. All ESBL-producing bacteria were classified 
as being MDR.  
A frozen product was used in eight out of ten patients and enema was the 
preferred way of administration in all but one patient. This patient, indeed, 
presented a compromised neurological status due to a cerebral 
toxoplasmosis and she was not considered eligible for enema. Median 
31 
 
quantity of donor stools was 84 g (range 43-104). At the time of FMT 
patients neutrophil count was > 1 x 109/L in all patients but one that had 
a neutrophil count of 0.17 x 10^9/L (the one with steroid-resistant 
GVHD). Platelet count was count > 20 x 109/L in all patients.  
Three patients required a second FMT: in one patient, after initial efficacy, 
VRE was again detectable 2 months after the first FMT. Of note, this 
patient developed multiple infectious episodes (particularly sinusitis and 
pneumonia), prompting to the frequent use of large spectrum antibiotics, 
thus probably leading to recurrence of VRE colonization. In the other two 
patients a second attempt was done due to the failure of the first 
procedure. In one patient this was mainly attributable to incorrect 
preparation with PEG. After a second attempt with a correct preparation, 
indeed, VRE eradication was achieved and persisted until 20 months after 
FMT. At that time, indeed, VRE was detectable contemporarily to 
hematologic disease recurrence. In the last patient, first and second FMT 
mainly had a compassionate aim in order to treat active grade IV gut 
GVHD and contemporarily multiple infectious episodes rendering 
impossible antibiotics withdrawal, even during the 72 hours following FMT, 
as detailed below.  
Globally, major decolonization (three consecutive negative microbiological 
cultures) was achieved in 7 out of 10 patients, including two patients after 
a second FMT (Figure 4). Persistent decolonization (negative 
microbiological cultures at last follow-up) was achieved in 6 out of ten 
patients after a median follow-up of 13 (range 4-40) months from FMT. As 
32 
 
already mentioned, indeed, one patient presented a positive rectal swab 
for ERV 20 months after FMT meanwhile to disease relapse. She finally 
died due to hematological progression.  
 
Figure 4. Results of fecal microbiota transplantation 
Failure occurred in the remaining three patients. The patient undergoing 
FMT with a compassionate aim had presented multiple infectious episodes 
from CP-Pseudomonas aeruginosa, rendering it impossible to stop 
antibiotics during the 72 hours after FMT. Moreover, grade IV gut GVHD 
was associated to intestinal occlusion, with need for an aspirating 
nasogastric tube, at time of FMT. Despite two attempts with FMT, the 
procedure was a failure and the patient finally died. In the second patient, 
due to the difficulties encountered in the positioning of a nasogastric tube, 
FMT was administered by enema and the patient was not able to retain 
the product for the advised 2 hours. She then refused a second attempt. 
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The third patient underwent FMT by enema from an unrelated donor and 
the hypothesis for FMT failure was that she received an insufficient 
quantity of stools (43 g), but what seems discordant with this hypothesis 
is that partial decolonization from concomitant ESBL-producing 
entrobacteriaceae was achieved. A second attempt in this patient was not 
possible due to the unavailability of additional material.   
Among the six patients concomitantly colonized from ESBL-producing 
entrobacteriaceae, three obtained concomitant decolonization.  
Details on FMT performed before or after allo-HSCT are reported in Table 
1.  
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 Table 1. Characteristics of patients undergoing fecal microbiota transplantation before (a) or after (b) hematopoietic stem cell transplantation.  a) 
 1 2 3 4 
Patient sex M M F M 
Age at time of FMT, years 64 42 45 47 
Hematologic malignancy AML AML AML BPDCN 
Identified MDRB CP- Pseudomonas 
aeruginosa 
CP-Pseudomonas 
aeruginosa 
CPE CPE° 
Antimicrobial resistance category XDR MDR MDR MDR 
Concomitant MDR-ESBL-producing bacteria 
colonization, bacteria  
Y N Y N 
Systemic infections due to MDRB before FMT  Y N N N 
Time from FMT to allo-HSCT (days) 41 46 16 9 
FMT donor Daughter Sister Husband Sister 
Way of administration Enema  Enema  Enema Enema 
Major decolonization Y Y Y Y 
Persistent decolonization Y Y Y Y 
Concomitant ESBL-producing bacteria 
decolonization 
Y N/A N N/A 
Follow-up after FMT, days 820 368 148 399 
Follow-up after allo-HSCT, days 779 322 132 390 
Status Alive Dead Alive Alive 
Cause of death N/A  Disease progression N/A N/A 
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Table 2. Characteristics of patients undergoing fecal microbiota transplantation before (a) or after (b) hematopoietic stem cell transplantation.  b) 
 5 6 7 8 9 10 
Patient sex F M F F F F 
Age at time of FMT, years 50 54 16 19 62 54 
Hematologic malignancy MPN MPN AML ALL MPN ALL 
Identified MDRB CP- 
Pseudomonas 
aeruginosa 
CP- 
Pseudomonas 
aeruginosa 
VRE VRE CPE  CPE  
Antimicrobial resistance category PDR XDR XDR XDR MDR XDR 
Concomitant MDR-ESBL-
producing bacteria colonization 
N Y Y Y  N Y  
Systemic infections due to MDRB 
before FMT 
Y Y N N N N 
Time from allo-HSCT to FMT 324 344 98 160 123 167 
FMT donor  Husband  Unrelated Mother Mother  Brother Unrelated 
Way of administration Nasogastric 
tube 
Nasogastric 
tube 
Enema Enema  Enema  Enema 
Second FMT N Y Y Y N N 
Time from first to second FMT, N/A 27 118 84 N/A N/A 
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days 
Major decolonization Y N Y Y N N 
Persistent decolonization Y N/A Y N N/A N/A 
Concomitant ESBL-producing 
bacteria decolonization 
N/A N N Y N/A Y 
Colonization relapse N N/A N Y N/A N/A 
Follow-up after FMT, days 678 33 1220 595 184 307 
Follow-up after allo-HSCT, days 1002 404 1436 839 307 474 
Status Alive Dead Alive Dead Alive Alive 
Cause of death N/A Uncontrolled 
GVHD and 
infection 
N/A Disease 
progression 
N/A N/A 
 
° 3 different types: Citrobacter freundii, Klebsiella Pneumoniae, Enterobacter Cloacae 
Abbreviations: F, female; M, male; FMT, fecal microbiota transplantation; AML, acute myeloid leukemia; BPDCN, 
blastic plasmacytoid dendritic cell neoplasm; MDRB, multidrug-resistant bacteria; CP, carbapenemase-producing; 
CPE, carbapenemase-producing Enterobacteriaceae; XDR, extensively-drug resistant; MDR, multi-drug resistant; 
ESBL, extended-spectrum beta-lactamase; Y, yes, N, no; allo-HSCT, allogeneic hematopoietic stem cell 
transplantation; GVHD, graft-versus-host disease; N/A, not applicable; MPN, myeloproliferative neoplasm; ALL, 
acute lymphoblastic leukemia; VRE, vancomycin-resistant enterococci; PDR, pan-drug resistant.  
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As an example of successful FMT, Figure 5 shows the case of the 
patient undergoing FMT from nasogastric tube, after experiencing 
breakthrough infectious episodes related to colonization from CP-
Pseudomonas aeruginosa, with need for continuous in hospital care 
during the first year after allo-HSCT. After FMT, this patient did not 
experience any other infectious episode and outpatient care was 
finally possible.   
 
 
Figure 5 Example of a successful fecal microbiota       
transplantation in patient 5. 
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According to the safety of FMT procedure, one patient presented 
constipation during the first 5 days after FMT which was favorably 
resolved after the use of laxatives, while two patients presented 
grade I diarrhea the day after FMT. No other major adverse events 
were observed. Six patients were discharged from the hospital 24 
hours after FMT was performed.  
Only one patient undergoing FMT before allo-HSCT developed a grade 
III acute gut graft-versus host disease at day +30 after allo-HSCT 
and at day +51 after FMT. Differential diagnosis with CMV colitis was 
evoked, and she favorably evolved after both antiviral and steroid 
treatment.   
When looking at severe infectious episodes during the 90 days 
following FMT, in two of those patients undergoing FMT before allo-
HSCT, documented bacteriemia without sepsis occurred early after 
allo-HSCT, favorably evolving after the introduction of large-spectrum 
antibiotics. In particular, one patient experienced a documented 
bacteriemia from multi-sensible Pseudomonas aeruginosa at day +80 
after allo-HSCT while the other patient experienced a documented 
bacteriemia from an ESBL-producing Escherichia Coli at day 60 after 
allo-HSCT. The additional two patients undergoing FMT before allo-
HSCT also received large spectrum antibiotic such as piperacillin-
tazobactam or cephalosporins for febrile neutropenia without 
documentation. Interestingly, despite the use of large spectrum 
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antibiotics, no cases of MDRB recurrence were observed in those four 
patients.   
Of note, fungal and viral infections were observed in only one patient 
more than 6 months after FMT but these were not considered in 
relation to FMT because this patient was under systemic 
immunosuppressive treatments for a cortico-resistant extensive 
GVHD (lung, skin, mucosal) and infectious episodes exacerbated 
during immunosuppressive treatment. Among the other patients, 
neither fungal nor viral infections were observed.  
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4. DISCUSSION 
Increasing emergence and diffusion of MDRB represents a major 
public health problem, with higher mortality in patients experiencing 
infections, and high costs of prolonged in-hospital care and 
preventive measures used to limit diffusion to other patients53,67.  
Human gut microbiota, also named as “gut resistome”, is the primary 
site for MDRB acquisition and colonization, being an important 
reservoir of antibiotic resistance genes (ARB)68.  Patients diagnosed 
with hematological malignancies are at high risk of colonization from 
MDRB: conditioning regimens for allo-HSCT and intensive 
chemotherapy, indeed, significantly alter the gastrointestinal barrier 
and, subsequently, the composition of intestinal microbiota is largely 
modified. Moreover, patients affected by hematologic malignancies or 
undergoing allo-HSCT are at particular risk for MDRB colonization or 
infection due to the large, prolonged and, sometimes, improper use 
of large spectrum antibiotics51. Of note, most bloodstream infections 
in hematological patients derive from the gut, and infections are even 
more severe in those patients undergoing allo-HSCT, with high 
mortality rates of 36-95%55,56. 
It has been largely reported that microbioma modifications are 
associated to worse survival, higher risk of infections and GVHD in 
patients undergoing allo-HSCT69,70.  Therefore, efficacious 
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decolonization strategies in this particular setting of patients are 
urgently needed.  
Fecal microbiota transplantation is a fascinating decolonization 
strategy, that has been proven to be efficacious in patients with 
recurrent CDI71. On the other hand, concerns were initially raised for 
the use of FMT as a decolonization strategy in immunocompromised 
patients, due to the possible risk of local or systemic infections after 
the inoculum of microbiota pathogens.        
Recently, DeFilipp et al. investigated the use of third-party FMT with 
the use of oral capsules, as a strategy to restore microbioma diversity 
in patients undergoing allo-HSCT. They support the safety and 
feasibility of this procedure underlying the possibility that microbiome 
restauration early after allo-HSCT may be of benefit50.   
Herein, we describe the results of FMT in 10 patients diagnosed with 
hematologic malignancies and undergoing FMT for MDRB colonization, 
namely CPE, CP-Pseudomonas aeruginosa or VRE, either before or 
after allo-HSCT. Decolonization was achieved in 7 out of 10 patients, 
this being persistent at last follow-up in 6 out 10 patients.  
Our retrospective study not only suggests the efficacy of this 
procedure, but also its safety in patients with hematologic 
malignancies and undergoing allo-HSCT.   
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Of note, despite not being a selection criterion for FMT, we also 
registered patients concomitantly colonized from ESBL-producing 
entreobacteriaceae, with decolonization in 3 out of 6 cases.   
We also showed that, in patients experiencing failure or relapse of 
MDRB colonization, a second FMT is feasible and efficacious.  
Interestingly, only three patients experienced significant infections 
after FMT.    
Moreover, it is worth underlying the significant benefit of major 
decolonization in the patient who had experienced multiple infectious 
episodes due to a CP-Pseudomonas aeruginosa, limiting breakthrough 
infections.   
Our results also highlight that despite administration of large 
spectrum antibiotics may hypothetically represent a risk of 
decolonization failure, the procedure remained effective in the 
majority of patients, without recurrence of MDRB in the majority of 
them despite use of broad spectrum antibiotics early after FMT. 
Of note, in one patient VRE was detectable again at the time of 
disease relapse, despite no use of large-spectrum antibiotics just 
before this detection. One can speculate that disease relapse may 
have probably been associated to dysbiosis favoring selection of VRE, 
but conclusions cannot be drawn on one case.   
The use of FMT represents an attractive strategy for MDRB 
decolonization, allowing intestinal microbiota modulation with 
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subsequent reconstitution of a healthy microbiota. Historically, FMT 
was first used in recurrent and severe CDI, and it has also shown 
promising activity in bowel disease40,36,72. Infusion of donor faeces in 
patients with CDI allowed improvement in gut microbial diversity, 
which persisted over time. Experience in the MDRB field is more 
recent, with several case reports and small series in different subsets 
of patients73,74,75.  
Despite the initial aforementioned concerns in immunocompromised 
patients, results of FMT in this setting are promising in terms of both 
efficacy and safety56,45,39. A recent prospective study showed, indeed, 
that FMT allowed total eradication of MDRB in 60% of cases, without 
any significant adverse event after the procedure64.  The latter is the 
only prospective study published to date using FMT in 20 patients 
with blood disorders and colonized with MDRB. Differently from our 
series, in this study all types of MDRB were included and only a few 
patients underwent allo-HSCT.  
In our Center, we only chose patients colonized with highly resistant 
bacteria and in particular those classified as eXDR according to 
French guidelines or those known to cause a significant higher risk of 
systemic infection with very poor prognosis (i.e. CP-Pseudomonas 
aeruginosa).  
To date, there are no specific guidelines on the ideal timing, the best 
preparation of stools for FMT, and the best way of administration. In 
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our experience, FMT was successfully undertaken either before or 
after allo-HSCT and, interestingly, it was also successful in two 
patients starting conditioning regimen for allo-HSCT 3 days after FMT.  
As for stool preparation, frozen material was preferred in our Center 
particularly due to logistic reasons, although in two cases fresh stools 
were used, but this did not modify the results of FMT. It has recently 
been reported in a meta-analysis of patients receiving FMT for CDI, 
that the success rate of FMT was similar when using frozen or fresh 
stools76. Differently from most of the reported series of FMT for MDRB 
decolonization, we preferred enema as a way of administration, as 
this is associated with lower risk of inhalation as compared to 
nasogastric administration.   
The mechanisms underlying the efficacy of FMT for MDRB 
decolonization are still not clear. In mice, antibiotic treatment allows 
intestinal colonization by VRE, and FMT is able to eradicate it 77.  
In humans, initial lessons from FMT in CDI may help understand the 
pathophysiology of MDRB decolonization. One study showed that 
patients experiencing recurrent CDI present a significant dysbiosis, as 
they harbor a high number and a wide variety of ARB, as compared 
to healthy stool donors 78. It seems that use of FMT may restore a 
more physiological microbioma by lowering the load of ARB, thus 
highlighting the possibility that FMT may eradicate MDRB and allow 
restoration of antibiotic susceptibility.  
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In our series, after FMT, almost all patients did not experience major 
infectious complications during the first 3 months after FMT and, of 
note, in those patients subsequently undergoing allo-HSCT, no severe 
infectious bacterial complications occurred during the early transplant 
phase. This suggests a possible protective role of the restoration of a 
healthy microbiota in preventing severe infections, but numbers are 
too low to draw significant conclusions. 
Regarding the impact of FMT on GVHD, only one of our patients had a 
grade IV acute gut GVHD concomitant to a carbapenemase-producing 
Pseudomonas aeruginosa at the time of FMT. In this specific case, the 
procedure was not efficacious neither for MDRB nor for GVHD. 
However it is worth underlying that FMT was performed at a very late 
stage (“compassionate” use), that may also explain failure of the 
procedure. Importantly, among the nine remaining patients, only one 
experienced grade III acute gut GVHD after FMT (with a possible 
differential diagnosis with CMV colitis). A role of FMT in causing GVHD 
in this patient cannot formally be excluded and this point may be 
addressed in a prospective clinical trial.  
Early studies in mice and humans suggested a link between gut 
microbiota and propensity to GVHD, with mice treated with gut-
decontaminating antibiotics developing GVHD less often 79,80. Recent 
results of a pilot study also highlight the possible advantage of 
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microbiota modulation with FMT in patients affected by steroid-
refractory or steroid-dependent GVHD 47.  
With regards to donor choice, people living in the same household of 
the patient were preferred, when available, as they widely share the 
same pathogens and environment exposure, thus reducing the risk of 
transferring additional infectious agents from the donor to the 
recipient. 
In line with previous reports, we consider that targeting gut 
microbiota in patients with impaired immune reconstitution in an 
attempt to reinstate a more equilibrated flora may favor stable 
eradication of the carrier status and prevent subsequent life 
threatening infections.  
We are well aware of the limits of our study, being a retrospective 
one, including a low-number of patients, with non-homogeneous 
inclusion criteria and differences in FMT procedure according to 
patients, so that definitive conclusions cannot be drawn.   
However, we consider that our results support the use of FMT as a 
promising strategy to manage the considerable potential risks 
associated with the MDRB carrier status in immunocompromised 
patients with intestinal dysbiosis and in those patients having 
experienced single or multiple systemic infections, with absence of 
breakthrough infections after decolonization and absence of MDRB 
recurrence despite the use of broad spectrum antibiotics in the 
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majority of them. Furthermore, our results support again the safety 
of the procedure in this population, despite previous concerns in 
immunocompromised patients. These preliminary results underline 
the need for further prospective studies on the safety and efficacy of 
FMT. 
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